<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04082039</url>
  </required_header>
  <id_info>
    <org_study_id>2019GR0294</org_study_id>
    <nct_id>NCT04082039</nct_id>
  </id_info>
  <brief_title>Two-channel Intravenous Patient-controlled Analgesia (IV-PCA) After Total Laparoscopic Hysterectomy (TLH)</brief_title>
  <official_title>The Efficacy of New Design Dual Channel Elastomeric Pump for Intravenous Patient-controlled Analgesia After Total Laparoscopic Hysterectomy: a Randomized, Double-blind, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Guro Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the dual channel intravenous patient-controlled
      analgesia (IV-PCA) with single channel elastomeric pump (only one channel of dual channel
      pump is used for blinding and the other channel is filled with same volume of saline) in
      patients undergoing total laparoscopic hysterectomy, in terms of quality of recovery,
      efficacy of postoperative pain, drug consumption, adverse event, and patient subjective
      satisfaction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Bellomic® M silicone balloon infuser, dual continuous petite type (cebika, Uiwang-si,
      Gyeonggi-do, Republic of Korea) is a newly designed IV-PCA device that is a 2-channel
      infusion elastomeric pump with two balloon chambers.

      Conventional elastomeric IV-PCA devices were administered with a mixture of drugs in one
      chamber; when severe opioid related side effects occur, the IV-PCA administration is
      suspended by clipping, in this situation, not only the analgesic effect of opioid but also
      the effect of adjuvants could not be applied.

      On the other hand, this newly designed device can be controlled as needed by administering
      adjuvant analgesics or antiemetic agents through another adjustable chamber. It will be
      expected that facilitate the pain management and increased the patient satisfaction and
      recovery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Korean version of the Quality of Recovery-40 questionnaire (QoR-40K) score</measure>
    <time_frame>At postoperative 24 hour</time_frame>
    <description>Patient recovery measured by QoR-40K score (maximum score 200)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain level was evaluated according to a numeric rating scale</measure>
    <time_frame>At 6, 12, 24, 36, 48 hours after surgery</time_frame>
    <description>(NRS; 0-100; no pain [0] to worst pain imaginable [100])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative consumption of PCA over 48 hours</measure>
    <time_frame>At postoperative 48 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The patient's overall satisfaction score</measure>
    <time_frame>At postoperative 48 hour</time_frame>
    <description>(0-10; 0 = un-satisfied to 10 = full-satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse effects</measure>
    <time_frame>Participants will be followed for their entire hospital stay, an expected average of 3-4 days</time_frame>
    <description>nausea and vomiting, dry mouth, dizziness, urinary retention, headache, sedation, itchiness, shivering, respiratory depression, confusion, hypotension, and bradycardia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Total Laparoscopic Hysterectomy</condition>
  <condition>Patient-controlled Analgesia</condition>
  <arm_group>
    <arm_group_label>1-channel PCA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ch-1: fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline) Ch-2: 100ml normal saline only (for blinding)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-channel PCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ch-1: fentanyl 16 µg/kg (total volume 100 ml with normal saline) Ch-2: ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>convetional PCA method unsing only 1-channel</intervention_name>
    <description>Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline); Ch-2 (flow 2ml/h): 100ml normal saline only (for blinding)</description>
    <arm_group_label>1-channel PCA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>utilizing 2-channel</intervention_name>
    <description>Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg (total volume 100 ml with normal saline; Ch-2 (flow 2ml/h fixed): ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)</description>
    <arm_group_label>2-channel PCA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient who was scheduled to undergo elective TLH under general anesthesia, was a
             female aged 19-75 years, and had an American Society of Anesthesiologists physical
             status I-II

        Exclusion Criteria:

          -  body mass index &gt; 30.0 kg/m2, known hypersensitivity to the drugs used in this study,
             significant liver or renal dysfunction, or a history of drug abuse or dependence,
             recent major procedure or surgery, or preoperative analgesic use
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seok Kyeong Oh, M.D.,PhD</last_name>
    <phone>82-2-2626-3237</phone>
    <email>nanprayboy@korea.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anaesthesiology and Pain Medicine, Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seok Kyeong Oh, M.D., Ph.D</last_name>
      <phone>82-2-2626-3237</phone>
      <email>nanprayboy@korea.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Guro Hospital</investigator_affiliation>
    <investigator_full_name>Seok Kyeong Oh</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>In order to protect patient priavacy and personal information, we will limit the provision of individual participant data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

